Trials / Completed
CompletedNCT00251888
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (planned)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
Detailed description
To determine the maximum and the recommended tolerated dose of irinotecan with increasing doses associated with weekly cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer, IIB-IVA FIGO stage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | campto (irinotecan) | |
| DRUG | cisplatin (cisplatyl) |
Timeline
- Start date
- 2002-11-01
- Completion
- 2005-11-01
- First posted
- 2005-11-11
- Last updated
- 2017-01-25
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00251888. Inclusion in this directory is not an endorsement.